Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care for neurodegenerative disease and the management of prostate cancer and metastatic liver tumors. The two organizations have signed an agreement that will improve care for those disease states and expand access to new imaging and interventional technologies.
Initial areas for collaboration include:
- Neurodegenerative disease: Advancement and clinical translation of AI-enabled MRI protocols for improved diagnostic accuracy and patient monitoring
- Surgical care pathway innovation: Applying digital twin technologies to re-imagine how patients experience surgery, enhancing their experience and improving operational efficiency
- Prostate cancer: Jointly investigating the role of AI in minimizing biopsies and integration of minimally invasive, advanced imaging into diagnostic and therapeutic procedures
- Minimally invasive, image-guided interventional suites: Clinical translation of image-guided technologies for the precise detection and treatment of liver metastases
- Ultra-high-field MRI innovation center: Clinical adoption and translation of ultra-high-field MRI protocols, taking advantage of the technology’s high resolution and enhanced contrast for diagnostic and surgical planning in complex neurological disease states
- Whole Body PET/CT & PET/MR innovation center: Adoption and clinical integration of whole-body PET/CT emphasizing theranostics treatment for certain cancers and simultaneous anatomical and metabolic MR imaging to enable precise diagnostic and therapeutic planning
“Our goal is to make care more precise, less invasive, and more responsive to each patient’s needs,” said Eric Williamson, M.D., professor and chair, diagnostic radiology, Mayo Clinic. “By expanding our collaboration, we can bring advanced imaging, artificial intelligence, and innovative treatment approaches directly into everyday clinical care, potentially helping patients receive earlier diagnoses, more personalized treatment plans, and better outcomes.”
Added John Kowal, president and head of the Americas at Siemens Healthineers: “Improving the diagnosis and treatment of neurodegenerative disease and cancer is core to our purpose as a company. Our collaboration with Mayo Clinic creates significant opportunities to help extend the quantity and quality of patients’ lives.”
Media Contacts
Siemens Healthineers
Julie Gibson
+1 917 929-5779
julie.gibson@siemens-healthineers.com
Visit the Siemens Healthineers Press Center.
Subscribe to our “Medtech matters” newsletter on LinkedIn.
Mayo Clinic
Tom Millikin
Mayo Clinic Communications
newsbureau@mayo.edu
Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at siemens-healthineers.com.
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
